Targeted Antibody-Drug combo shows promise for Hard-to-Treat lung cancer
NCT ID NCT07662473
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the drug trastuzumab deruxtecan (T-DXd) in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has high levels of the HER2 protein. Participants receive T-DXd by IV every three weeks. The study measures how long the cancer stays under control and overall survival. It enrolls about 30 adults whose cancer has worsened after at least one prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab deruxtecan (T-DXd)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced lung cancer that overproduces HER2 protein.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply broadly. The drug can cause serious side effects like lung inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?